此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

炎症性关节炎患者安全技能自我管理智能手机应用的有效性 (RHUMATOSMART)

2026年11月5日 更新者:Assistance Publique - Hôpitaux de Paris

抗风湿药物治疗的炎症性关节炎患者安全技能促进中自我管理智能手机应用程序的疗效

Rheumatoid arthritis (RA) and spondyloarthritis (SpA), including psoriatic arthritis (PsA), are chronic painful diseases that impair quality of life. Disease-modifying antirheumatic drugs (DMARDs) are used to control disease activity, reduce functional disability, and improve prognosis. These include conventional DMARDs such as methotrexate, as well as targeted DMARDs (tDMARDs), i.e., biological agents (bDMARDs) like anti-TNF alpha and JAK inhibitors. Patients treated with tDMARDs face a risk of adverse effects, including an increased risk of infections. Therapeutic patient education has been shown to help patients develop safety skills, but its effectiveness is only short-term.

Mobile health applications are increasingly used by patients to manage their health.

The French Society of Rheumatology (SFR) has developed a smartphone self-management application aimed at supporting people with inflammatory arthritis in managing their treatments, symptoms, and information needs. It provides advice on lifestyle and daily living, promotes treatment adherence, and enables self-assessment of disease status. The app includes seven features: a safety checklist before treatment administration, daily life aids based on French academic recommendations, treatment reminders, self-assessment of overall well-being, disease monitoring (pain, fatigue, patient global assessment of disease activity), periodic advisory messages, and a diary.

The application is not a medical device; collected data are stored on the user's smartphone. Patient data are not directly shared with physicians. Patients can use the app during consultations or share screenshots with their doctors. The app is more widely used and has a longer lifespan than most available apps, but its impact on patients still needs evaluation in a randomized controlled trial.

The primary hypothesis of the study is that using the app will improve safety skills in patients with inflammatory arthritis treated with tDMARDs compared to usual care, including access to the SFR patient information website.

The secondary hypothesis is that using the app will improve patient adherence and the patient-rheumatologist relationship.

Objectives : To determine whether the mobile application improves patients' ability to acquire safety-related skills in the daily use of targeted disease-modifying antirheumatic drugs (tDMARDs), compared to usual care, including access to an informational website for patients.

The primary outcome will be the change in the BioSecure questionnaire score at 6 months after inclusion, comparing the group using the mobile application with the group using the informational website.

研究概览

详细说明

Rheumatoid arthritis (RA) and spondyloarthritis (SpA) including psoriatic arthritis (PsA) represent painful chronic conditions impairing quality of life and work capacities. Disease-modifying anti-rheumatic drugs (DMARDs) are used to control inflammatory Arthritis (IA) disease activity, reduce functional disability and improve prognosis. They include conventional DMARDS (cDMARDs) such as methotrexate, targeted DMARDs (tDMARDs) i.e biologic agents (bDMARDs) such as tumor necrosis factor (TNF) alpha blockers, and Janus-kinase inhibitors (JAKi). The number of DMARDs is increasing (more than 15 DMARDs in France) and have a wide variety of targets and modes of administration . Patients treated by DMARDs are at risk of adverse events, including excess risk of infection, noted more in RA than SpA , in particular because of co-medication with glucocorticoids and/or high disease activity. Measures patients can take to decrease these risks include vaccinations , self-referral and DMARD interruption in some situations such as surgery, dental care or pregnancy, which patients need to discuss with health professionals. A nurse-led patient education has been shown to be effective in promoting safety skills of patients treated by biologics but education is not routinely provided in all rheumatology centres. Moreover, patient education is effective in the short term only, not exceeding 6 months .

Mobile health applications (mhealth apps) have undergone significant development in recent years and are of increasing interest and usefulness to help patients manage their chronic inflammatory arthritis (IA) . With reference to the well-established definition of self-management . that is, "the ability of the individual to manage symptoms, treatment, lifestyle changes and psychosocial and cultural consequences of health conditions", Apps may be appropriate tools for self-management such as medications management, problem-solving, and care coordination or to offer a more holistic approach . However, an app providing information to help patients be more aware of their medications in daily life and adopt appropriate behaviours with risk situations had not been addressed in IA.

In this context, the French Society of Rheumatology ( SFR) developed a self-management smartphone app, with the objective of helping IA people with their treatments, symptoms, and information needs, provide healthy lifestyle and daily life messages and promote adherence to medication and disease self-assessment . The app includes seven functionalities: a safety checklist before treatment administration, aids in daily life situations based on the French academic recommendations, treatment reminders, global well-being self-assessment, disease monitoring (pain, fatigue, patient global assessment (PGA) of disease activity), periodic counselling messages, and a diary. The app is not a medical device, data collected are stored within the user's smartphone. Patients' data are not to be directly communicated to the physicians, but patients can make screenshots of their app to communicate with their physician. The app was installed 20,500 times from September 2017 to October 2020 (nowadays 30,000 downloads), with 4300 regular current users. Scores were 4.4/5 stars at Android and iOS stores . The SFR app is the first published app with respect to medication management, all the more in France where very few health apps are available. Apart from SFR app, only one app has been published on medication management, tested on 85 patients . The SFR app is more widely used and has a longer lifespan than most apps available in IA: in the studies by EULAR, 75% people had stopped using m-health apps after 3 months for rheumatic and musculoskeletal diseases and only 5% of these apps were still available 2 years after their launch . Assessment of the impact of the SFR app is important since patients are more likely to download and use the app if it has a proven benefit and 2/3 of patients would use it if recommended by their physicians . Therefore, the impact of SFR app needs to be evaluated in a randomised controlled trial.

The first hypothesis of the study is that the use of the SFR app would promote safety skills of patients with IA treated with DMARDs, compared with usual care including access to a SFR patient information website.

The secondary hypothesis is that the use of the SFR app would promote adherence to tDMARDs and patient-rheumatologist's relationship.

研究类型

介入性

注册 (估计的)

144

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Paris、法国、75012
        • 招聘中
        • Rheumatology Hopital Saint Antoine
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Age between 18 and 75 years
  • Diagnosis of rheumatoid arthritis (RA) according to the 2010 ACR/EULAR classification criteria of the American College of Rheumatology, or axial or peripheral spondyloarthritis (SpA) according to the 2009 ASAS criteria of the Assessment of SpondyloArthritis International Society, or psoriatic arthritis according to the 2009 CASPAR criteria.
  • Undergoing a treatment change to a tDMARD (biologic or JAK inhibitor) available in the SFR application.
  • No therapeutic education on tDMARDs in the past two years.
  • Ability to use a smartphone application.
  • Ability to use a website.
  • Ability to complete a questionnaire.
  • Signed informed consent for the study.
  • Covered by social security or entitled to social protection.

Exclusion Criteria:

  • Any condition that may affect comprehension or treatment adherence (chronic alcoholism, language barrier, severe psychiatric disorders, cognitive impairment).
  • Planned treatment with intravenous bDMARDs in the upcoming year.
  • Patients who have already downloaded self-management applications for their rheumatic disease.
  • Patients enrolled in a therapeutic education program: face-to-face education by a nurse or healthcare professional, or group education.
  • Patients who have already received therapeutic education on targeted DMARDs in the past two years: face-to-face education by a nurse or healthcare professional, or group education.
  • Participation in another interventional clinical trial
  • Pregnant or breast-feeding woman
  • Individual under legal protection (tutorship or guardianship) or deprived of freedom

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:支持治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Mobile Application

Patients in the intervention group will upload the SFR app

The app includes seven functionalities: a safety checklist before treatment administration, aids in daily life situations based on the French academic recommendations, treatment reminders, global well-being self-assessment, disease monitoring (pain, fatigue, patient global assessment (PGA) of disease activity), periodic counselling messages, and a diary.

无干预:information web site

Patients of both group willreceive a link that will give them access to SRF web site

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
safety skills regarding the use of tDMARDS
大体时间:6 month

safety skills regarding the use of tDMARDS will be assessed by the change of the updated BioSecure questionnaire score at 6 months from baseline in the SFR mobile app group versus the control group.

The scores ranges from 0 to 50. A higher scores represents higher safety skills.

6 month

次要结果测量

结果测量
措施说明
大体时间
Adherence to tDMARDs
大体时间:6 month

Adherence to tDMARDs assessed by the CQR5 questionnaire score (rate of adherent patients).

The scores ranges from 4 to 20, with a high score indicating better adherence.

6 month
patient-rheumatologist communication
大体时间:6 month

Patient-rheumatologist communication assessed by the PEPPI-5 questionnaire score (Perceived Efficacy in Patient-Physician Interactions).

The scores ranges from 0-50; higher scores represent higher perceived self-efficacy in patient-physician interactions.

6 month
confidence in taking care of one's health
大体时间:6 month

Health confidence assessed by the HCS questionnaire (Health confidence score).

The scores ranges from 0 to 12. Higher score represents greater health confidence.

6 month
Impact on disease including coping to disease.
大体时间:6 month

Impact of disease assessed by the RAID questionnaire score (rheumatoid arthritis impact of disease).

6 month
Disease activity for rheumatoid arthritis
大体时间:6 months

Disease activity assessed by the RADAI (Rheumatoid Arthritis Disease Activity Index),

The scores ranges from 0-48, higher score meaning higher disease activity

6 months
Disease activity for axial spondyloarthritis
大体时间:6 months

Disease activity assessed by the BASDAI (Bath Ankylosing Spondylitis Disease activity).

The scores ranges from 0 to 10, higher score meaning higher disease activity.

6 months
Disease activity for psoriatic arthritis
大体时间:6 months

Disease activity assessed by SASPA (Stockerau Activity Score for Psoriatic Arthritis).

The scores ranges from 0 to 5, higher score meaning higher disease activity.

6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Catherine BEAUVAIS, Medical Doctor、Assistance Publique - Hôpitaux de Paris

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年8月31日

初级完成 (估计的)

2027年9月1日

研究完成 (估计的)

2027年9月1日

研究注册日期

首次提交

2026年1月5日

首先提交符合 QC 标准的

2026年3月4日

首次发布 (实际的)

2026年3月10日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅